Leerink analyst Mike Kratky downgraded Penumbra (PEN) to Market Perform from Outperform with a $374 price target after Boston Scientific (BSX) entered an agreement to acquire Penumbra in a cash and stock transaction valued at $14.5B, or $374 per share.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PEN: